Aposense plans $20 million Israeli IPO
This article was originally published in Scrip
Executive Summary
Aposense is planning to list on the Tel Aviv Stock Exchange. The Israeli firm, which designs small molecules that can identify and accumulate within apoptotic cells for use in molecular imaging and drug development, intends to raise around $20 million through an initial public offering in early June.